Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

Published:2020-07-12 Issue:5 Volume:192 Page:853-868
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jackson Graham H.¹,Pawlyn Charlotte²³^ORCID,Cairns David A.⁴^ORCID,Striha Alina⁴,Collett Corinne⁴,Waterhouse Anna⁴,Jones John R.⁵,Wilson Jamie⁶,Taylor Craig⁷,Kishore Bhuvan⁸,Garg Mamta⁹,Williams Cathy D.¹⁰,Karunanithi Kamaraj¹¹,Lindsay Jindriska¹²,Jenner Matthew W.¹³,Cook Gordon⁴¹⁴^ORCID,Russell Nigel H.¹⁰,Drayson Mark T.¹⁵,Kaiser Martin F.²³^ORCID,Owen Roger G.¹⁶,Gregory Walter M.⁴,Davies Faith E.¹⁷,Morgan Gareth J.¹⁷,

Affiliation:

1. Northern Institute for Cancer Research Newcastle University Newcastle upon TyneUK

2. The Institute of Cancer Research LondonUK

3. The Royal Marsden Hospital NHS Foundation Trust LondonUK

4. Clinical Trials Research Unit Leeds Institute of Clinical Trials ResearchUniversity of Leeds LeedsUK

5. Kings College Hospital NHS Foundation Trust LondonUK

6. Western Sussex Hospitals NHS Foundation Trust ChichesterUK

7. Russells Hall Hospital DudleyUK

8. University Hospitals Birmingham NHS Foundation Trust BirminghamUK

9. Leicester Royal Infirmary Leicester UK

10. Centre for Clinical Haematology Nottingham University Hospital NottinghamUK

11. University Hospital of North Midlands Stoke‐on‐TrentUK

12. E1ast Kent Hospitals University NHS Foundation Trust CanterburyUK

13. University Hospital Southampton NHS Foundation Trust SouthamptonUK

14. Leeds Cancer Centre University of Leeds Leeds UK

15. Clinical Immunology Service Institute of Immunology and Immunotherapy University of Birmingham BirminghamUK

16. Haematological Malignancy Diagnostic Service (HMDS) St James's University Hospital Leeds UK

17. Perlmutter Cancer Center NY Langone Health New York NY USA

Funder

Cancer Research UK

Celgene

Merck

Myeloma UK

Cancer Research Institute

University of Leeds

University of Birmingham

Royal Marsden NHS Foundation Trust

Institute of Cancer Research

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16945

Reference21 articles.

1. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

3. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

4. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

5. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

2. The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma;European Journal of Haematology;2023-12-19

3. Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma;Current Hematologic Malignancy Reports;2023-07-04

4. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study;Clinical Lymphoma Myeloma and Leukemia;2023-07

5. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review;Frontiers in Oncology;2023-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3